S
Subsense
Nanotechnology solutions for noninvasive brain-computer interfaces and neurodegenerative disease treatment
About Subsense
Subsense is a pioneering organization focused on developing advanced nanotechnology solutions to transform the field of noninvasive brain-computer interfaces (BCIs) and address neurodegenerative diseases. Operating primarily in the healthcare sector, Subsense targets both European and American markets, offering cutting-edge BCI technology designed for daily use. The company collaborates with esteemed professionals and academics, including experts from ETH Zurich and Stanford University, to ensure the highest standards in research and development. Subsense's business model revolves around creating and commercializing medical devices that integrate seamlessly into everyday life, providing significant benefits to patients and healthcare providers. By leveraging its expertise in nanotechnology, Subsense aims to generate revenue through the sale and licensing of its innovative BCI products. The company is committed to enhancing the quality of life for individuals affected by neurodegenerative conditions, positioning itself as a key player in the intersection of healthcare and technology.
Source: Dealroom company dataKnowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Dec 2025 | $10M | $85M | Golden Falcon Capital | ↗ |
| SEED✓Equity / VC | Feb 2025 | $17M | $68M | Golden Falcon Capital | ↗ |
Growth signals
Latest recorded traffic for Subsense is 7.1K monthly website visits, up 34% over the last three months. Subsense's team grew 680% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 INBRAIN NeuroelectronicsHigh-resolution graphene interfaces for precision neurology. |
Barcelona, Spain | Operational | 126 | $77M | $200M |
 Yuansi TechnologyBrain-computer interface decoding speech from brain signals. |
China | Operational | |||
 Morph LabsNon-invasive brain interface for intuitive prosthetic control. |
— | Operational | |||
 NeurogatiAI-powered neurotechnology for personalized neurological care. |
Chennai, India | Operational | |||
 Kyma NeuroAccessible brain-computer interface platform for researchers. |
New York City, United States | Operational | |||
 Niantong Intelligent TechnologyNon-invasive brain-computer interfaces for stroke rehabilitation. |
Huangpu, China | Operational | |||
 Epia NeuroIntent-driven neural interface for post-stroke recovery. |
Alameda, United States | Operational | |||
 UCANACTDigital device control for severe motor disabilities. |
Utrecht, Netherlands | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Golden Falcon Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Subsense on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Subsense’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.